Corporate Branding Design For The New Celsion-EGEN

Positioning A Cutting-Edge Biotech

Reality testing: Celsion, a global late-stage clinical oncology company, is focused on the development and commercialization of innovative cancer drugs, including proven targeted cancer therapies that work in combination to enhance the standard of care. EGEN, an early-stage biopharmaceutical company, specializes in the delivery of therapeutic nucleic acids (DNA and RNAi) aimed at specific disease targets. Celsion’s recent acquisition of EGEN results in a well-defined strategic fit, bringing discovery and preclinical expertise together with clinical and operational excellence, and uniting groundbreaking technologies with high-value assets.

Envisioning a new reality: Critical to gaining visibility and advancing the company’s multi-phase clinical pipeline was the development of a strategic corporate identity. Chosen as partner agency, REALITYRx is proud to be involved in an ongoing process of positioning the new Celsion-EGEN in the oncology market, quickly designing the transitional brand, communicating the key strategic benefits of the new company, and flawlessly executing and coordinating a multi-phase campaign rollout.

Inventing the reality: The meticulously planned launch ignited immense interest in the new company’s combined oncology pipeline, both among the clinical community and investors. An announcement campaign went live with a complete media kit, pipeline and summary posters, and an introductory platform video teaser, which was played at the July 16th, 2014 NASDAQ closing bell ceremony.

Helping the new Celsion-EGEN achieve heightened visibility, a three-pronged digital arm was incorporated to revamp the two companies’ websites with an eBlast series to drive traffic. On the next level of engagement, viewers can connect to the press release, which positions the new entity as one with a unique opportunity to transform the landscape of treating the world’s growing incidence of cancer.

Stay tuned to see how the campaign unfolds.


NASDAQ Closing Bell Ceremony

The agency joined Celsion-EGEN as they rang the NASDAQ closing bell in celebration of the acquisition and new combined pipeline

Celsion Video Takes Over Times Square

Celsion went big with the announcement of the EGEN acquisition, making sure that NYC investors took notice

Landing Page and Banners

Banners on each company website alert visitors to the acquisition, driving them to a newly designed landing page with more information about the companies’ synergistic alignment


Pipeline Poster

This poster makes it easy to visualize just how extensive the company’s pipeline has become, with ongoing clinical programs for a variety of cancer indications

Corporation Introduction Video

A short video teaser highlights the cutting-edge oncology platforms that come together under the new Celsion-EGEN, igniting audience interest

iPad App

This comprehensive resource houses clinical research and information about Celsion-EGEN’s leading platforms for investors, researchers, and scientists interested in the company’s progress




Positioning A Cutting-Edge Biotech

Reality testing: Celsion, a global late-stage clinical oncology company, is focused on the development and commercialization of innovative cancer drugs, including proven targeted cancer therapies that work in combination to enhance the standard of care. EGEN, an early-stage biopharmaceutical company, specializes in the delivery of therapeutic nucleic acids (DNA and RNAi) aimed at specific disease targets. Celsion’s recent acquisition of EGEN results in a well-defined strategic fit, bringing discovery and preclinical expertise together with clinical and operational excellence, and uniting groundbreaking technologies with high-value assets.

Envisioning a new reality: Critical to gaining visibility and advancing the company’s multi-phase clinical pipeline was the development of a strategic corporate identity. Chosen as partner agency, REALITYRx is proud to be involved in an ongoing process of positioning the new Celsion-EGEN in the oncology market, quickly designing the transitional brand, communicating the key strategic benefits of the new company, and flawlessly executing and coordinating a multi-phase campaign rollout.

Inventing the reality: The meticulously planned launch ignited immense interest in the new company’s combined oncology pipeline, both among the clinical community and investors. An announcement campaign went live with a complete media kit, pipeline and summary posters, and an introductory platform video teaser, which was played at the July 16th, 2014 NASDAQ closing bell ceremony.

Helping the new Celsion-EGEN achieve heightened visibility, a three-pronged digital arm was incorporated to revamp the two companies’ websites with an eBlast series to drive traffic. On the next level of engagement, viewers can connect to the press release, which positions the new entity as one with a unique opportunity to transform the landscape of treating the world’s growing incidence of cancer.

Stay tuned to see how the campaign unfolds.


NASDAQ Closing Bell Ceremony

The agency joined Celsion-EGEN as they rang the NASDAQ closing bell in celebration of the acquisition and new combined pipeline

Celsion Video Takes Over Times Square

Celsion went big with the announcement of the EGEN acquisition, making sure that NYC investors took notice

Landing Page and Banners

Banners on each company website alert visitors to the acquisition, driving them to a newly designed landing page with more information about the companies’ synergistic alignment


Pipeline Poster

This poster makes it easy to visualize just how extensive the company’s pipeline has become, with ongoing clinical programs for a variety of cancer indications

Corporation Introduction Video

A short video teaser highlights the cutting-edge oncology platforms that come together under the new Celsion-EGEN, igniting audience interest

iPad App

This comprehensive resource houses clinical research and information about Celsion-EGEN’s leading platforms for investors, researchers, and scientists interested in the company’s progress

Share This